Affymax, J&J, Takeda hematology news
Affymax said an arbitration panel determined that Johnson & Johnson is the sole owner of U.S. Patent No. 5,767,078 and related patents in Europe, Japan, Canada and Australia. The patents relate to methods of dimerizing and activating the erythropoietin (EPO) receptor. The panel also determined that Affymax and J&J co-own U.S. Patent Nos. 5,773,569; 5,830,851; 5,986,047 and others related to EPO receptor agonists.
Affymax said it does not believe the claims in the '078 patent are valid. It also said that its Hematide peginesatide does not infringe any of the claimed methods described in the patent. Affymax, which said the decision could allow J&J to sue upon a Hematide launch, said it is evaluating the decision to determine potential next steps in the litigation. ...